What Is BPC 157? A Clear, Honest Guide

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

What is BPC 157, exactly?

BPC-157 is a lab-made peptide built from a chain of 15 amino acids, which is why chemists call it a pentadecapeptide ("penta-deca" = fifteen). The name is short for "Body Protection Compound 157." Its amino-acid sequence corresponds to a fragment of a larger protein that researchers first identified in human gastric juice — the acidic fluid in the stomach. So while BPC-157 itself is synthetic and does not occur naturally in your body in this exact form, its sequence traces back to a naturally occurring gastric protein.

Because it is a peptide, BPC-157 is essentially a very short protein. Peptides are the messengers and building blocks of biology — insulin is a peptide, and so is the GLP-1 hormone that newer weight-loss medications mimic. That biological plausibility is part of why BPC-157 has drawn so much research interest. But interest and evidence are not the same thing, and that distinction is the theme of this whole guide.

One version, "stable gastric pentadecapeptide BPC 157," is described in the literature as unusually stable — able to hold up in the acidic environment of the stomach where many peptides would break down. That stability is part of the reason it became a research favorite. It's worth being precise, though: the sequence is inspired by a gastric protein, but the compound you'd see discussed online is manufactured synthetically in a lab, not extracted from anyone's body. In regulatory terms it sits in an awkward spot — sometimes marketed as a "research chemical," sometimes as a supplement, but recognized by the NIH's drug database as an unapproved drug substance. It is none of the reassuring things a label might imply.

Is BPC 157 a steroid?

No. This is one of the most common mix-ups, and the answer is unambiguous: BPC-157 is a peptide, not a steroid. The two are chemically unrelated. Anabolic steroids are lipid (fat-based) molecules built on a four-ring carbon skeleton, and they act like hormones such as testosterone. BPC-157 is a chain of amino acids with a completely different structure and no known anabolic, muscle-building hormonal action.

People sometimes assume anything used by athletes for "recovery" must be a steroid. It isn't. Grouping BPC-157 with steroids also muddies the real conversation, which is about evidence and sourcing — not about hormones. A quick side-by-side makes the difference concrete.

Feature	BPC-157 (a peptide)	Anabolic steroid
Building block	15 amino acids in a chain	Four-ring lipid (steroid) skeleton
Acts like	A signaling peptide (studied for tissue repair in animals)	A hormone, e.g. testosterone
Muscle-building?	No known anabolic action	Yes, directly anabolic
FDA status	Not approved; no legal medication pathway	Approved forms exist (prescription, controlled)

Why is BPC 157 called the "Wolverine peptide"?

The "Wolverine peptide" nickname is borrowed from the Marvel character famous for healing almost instantly. It caught on because a series of animal studies investigated whether BPC-157 could speed tissue repair. In rodent models, researchers looked at its effects on tendon, muscle, and bone healing, largely through the growth of new blood vessels (angiogenesis). Those results generated the flashy nickname.

Here's the honest framing: "Wolverine peptide" is a marketing label, not a clinical finding. Impressive results in a rat do not automatically translate to a human, and the researchers behind that foundational work explicitly acknowledged the absence of human trial data. We wrote a full explainer on where the nickname comes from and what the science actually shows in our breakdown of the "Wolverine peptide" nickname and the research behind it.

What has research actually investigated?

This is where precision matters most. Almost all of the BPC-157 literature is preclinical — meaning animal models and lab dishes, not controlled human trials. Below is a high-level map of what researchers have looked at. Nothing here is a proven human benefit.

Area studied	What research investigated	Evidence type
Tendon, muscle & bone repair	Faster wound and soft-tissue healing via angiogenesis (new blood-vessel growth)	Animal / preclinical
Gut & gastric protection	Effects on ulcers, NSAID-related damage, and colitis in rodent models	Animal / preclinical
Vascular / mechanism	A proposed angiogenesis and nitric-oxide (NO) system pathway	Animal / preclinical
Brain-gut axis	Cytoprotection and neurological signaling along the gut-brain connection	Animal / preclinical
Human hamstring strain	First controlled test of tissue repair in people	Registered trial — recruiting, no results

The tissue-healing work draws on wound- and tendon-healing studies in animals that credit angiogenesis as a central mechanism. A 2025 review proposed an angiogenesis and nitric-oxide-system explanation, while earlier work explored the brain-gut axis and gastric cytoprotection. Crucially, the first rigorous human study — a Phase 2 trial for acute hamstring strain — is only now recruiting and has produced no results. Independent reviewers put it plainly: efficacy looks high in rats, but there is little human evidence.

If you want the compliance-careful long version of what researchers have and haven't found, see our detailed look at what BPC-157 research has investigated. And because "what does it do" and "what could go wrong" are two sides of the same coin, read alongside the known and unknown BPC-157 side effects and safety gaps.

Is BPC 157 FDA-approved or legal to buy?

No — and this part gets misreported constantly, so here is the careful version. BPC-157 is not FDA-approved for any use. It is also not on the FDA's 503A Bulks List, the roster of substances that compounding pharmacies are permitted to use. Without that listing, there is no lawful pathway to compound or sell BPC-157 as a medication in the United States today. In September 2023, the FDA placed BPC-157 in its 503A "Category 2," flagged as posing a significant safety risk.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 and several other peptides under docket FDA-2025-N-6895. Ahead of that meeting, FDA staff proposed that these peptides not be added to the list, citing that they are poorly characterized, have little human efficacy evidence, and carry unresolved safety questions including unassessed immunogenicity.

Read that carefully. The committee is advisory and non-binding — a formal rule would still require notice-and-comment rulemaking. So the accurate statement is "FDA staff have proposed not to list BPC-157," not "the FDA banned it." Either way, the practical reality is the same today: there is no legal, prescribed product, and the FDA has issued dozens of warning letters to peptide vendors.

How should you think about BPC 157 safely?

Because there's no approved product, everything sold online today is gray-market — research chemicals from vendors with no medical oversight. That is where the real, present-day danger lives, and it's the single most important thing on this page.

The clearest data comes from a 2024 peer-reviewed analysis. Researchers bought injectable products from online sellers without a prescription and tested them. The findings: measured purity ran roughly 7.7% to 14.4% against the "99%" advertised, and endotoxin — a bacterial contaminant that can cause fever and worse — was present in 100% of the samples tested, with well over half failing basic visual quality checks. That study looked at semaglutide products, but it exposes the core problem with the entire unregulated injectable-peptide channel.

Here's the trap most buyers fall into: a "99% pure" certificate tests identity only — whether the molecule in the vial is what the label says. It does not test sterility or endotoxin. A vial can be genuinely pure and still be contaminated enough to make you sick. Add to that reports of wrong amino-acid sequences and heavy-metal contamination in research-grade peptides, plus the fact that human safety beyond a few weeks has never been established, and self-dosing a vial you bought online is a real gamble — not a health optimization.

This is exactly why the source of any peptide matters more than the marketing around it. For the fuller safety picture, see our guide to BPC-157 side effects and gray-market risks. If you're curious what dosing figures the literature has reported — strictly as background, never as a how-to — our BPC-157 dosage overview puts those numbers in their proper safety context. And because BPC-157 is often discussed alongside another peptide, our comparison of BPC-157 and TB-500 covers how the two differ.

Where Nouri fits: sourcing peptides safely

Nouri's position on peptides is simple and deliberately conservative: legitimacy first. We don't sell BPC-157, we don't imply it's available, and we won't put a price on a research chemical that has no legal, prescribed pathway. The reason people get hurt in this space isn't usually the molecule in theory — it's the unregulated vial in practice, the one with endotoxin in it and a certificate that only ever measured identity.

If and when a licensed, clinician-overseen, properly tested peptide option becomes available through a compliant channel, we want the people who trust us to hear about it first — from a source that led with the science and the safety, not the hype. You can join the peptide waitlist to be notified if that day comes. No preselling, no promised date, no product for sale today — just first notice through a legitimate channel.

Want to be first to know if licensed peptide options become available? Join the Nouri peptide waitlist — we'll only reach out if a compliant, prescribed option opens up.

Separately, if your actual goal is metabolic health and weight management, that's a category where real, prescription-based care already exists. Nouri's medically supervised weight-loss program is one option worth understanding. Note that compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro — a different topic from peptides like BPC-157, but the same principle applies: a licensed, prescribed channel beats a gray-market one every time.

Frequently asked questions

What is BPC 157? BPC-157 is a synthetic peptide made of 15 amino acids (a pentadecapeptide). Its sequence is derived from a protein region identified in human gastric juice. It is a peptide, not an anabolic steroid, it has been studied almost entirely in animals, and it is not FDA-approved.

Is BPC 157 a steroid? No. BPC-157 is a peptide — a short chain of 15 amino acids. Steroids are lipid-based hormones with a very different structure and mechanism. BPC-157 is not anabolic and does not act like testosterone or corticosteroids.

Why is BPC 157 called the Wolverine peptide? The nickname references the Marvel character known for rapid healing. It points to preclinical animal studies that investigated tissue repair. It's a marketing label, not a proven human effect — human clinical evidence is essentially absent.

Is BPC 157 FDA-approved or legal to buy? No. It is not FDA-approved and not on the 503A Bulks List, so there is no legal way to compound or sell it as a medication today. In July 2026, FDA staff proposed to the advisory PCAC that it not be listed; that committee is advisory and non-binding.

Is BPC 157 safe? Human safety data is essentially absent, and no approved product exists. The bigger near-term danger is the gray market: a 2024 peer-reviewed analysis of similar online injectables found endotoxin in 100% of samples and purity far below the advertised 99%. A "pure" label tests identity only — not sterility.

Has BPC 157 been tested in humans? Rigorous human testing is only just beginning. The first registered controlled human trial — a Phase 2 study for acute hamstring strain — is recruiting and has no results yet. Until such trials report, claims about human benefits are not supported by clinical evidence.

Sources & data

Primary sources: Seiwerth & Sikiric et al., "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing," Frontiers in Pharmacology (2021); Sikiric et al., Pharmaceuticals (Basel) (2025); Sikiric et al., "Brain-gut Axis and Pentadecapeptide BPC 157," Current Neuropharmacology (2016); ClinicalTrials.gov NCT07437547 — Phase 2 hamstring-strain trial; Examine.com — BPC-157 evidence overview; JMIR (2024) gray-market injectable quality analysis; and the Federal Register PCAC notice, docket FDA-2025-N-6895.

Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. This article is educational and is not medical advice.

Curious about legitimate, prescribed options in this space? Join the Nouri peptide waitlist — be first to know if and when a licensed, clinician-overseen peptide option becomes available.